| Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study P Miner Jr, PO Katz, Y Chen, M Sostek Official journal of the American College of Gastroenterology| ACG 98 (12 …, 2003 | 682 | 2003 |
| Treatment of chronic posterior laryngitis with esomeprazole MF Vaezi, JE Richter, CR Stasney, JR Spiegel, RA Iannuzzi, JA Crawley, ... The Laryngoscope 116 (2), 254-260, 2006 | 417 | 2006 |
| Naloxegol for opioid-induced constipation in patients with noncancer pain WD Chey, L Webster, M Sostek, J Lappalainen, PN Barker, J Tack New England Journal of Medicine 370 (25), 2387-2396, 2014 | 405 | 2014 |
| Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial TO Kiljander, SM Harding, SK Field, MR Stein, HS Nelson, J Ekelund, ... American journal of respiratory and critical care medicine 173 (10), 1091-1097, 2006 | 296 | 2006 |
| Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial R Fass, SJ Sontag, B Traxler, M Sostek Clinical Gastroenterology and Hepatology 4 (1), 50-56, 2006 | 171 | 2006 |
| Randomised clinical trial: the long‐term safety and tolerability of naloxegol in patients with pain and opioid‐induced constipation L Webster, WD Chey, J Tack, J Lappalainen, U Diva, M Sostek Alimentary pharmacology & therapeutics 40 (7), 771-779, 2014 | 156 | 2014 |
| A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced … L Webster, S Dhar, M Eldon, L Masuoka, J Lappalainen, M Sostek PAIN® 154 (9), 1542-1550, 2013 | 133 | 2013 |
| Method for delivering a pharmaceutical composition to patient in need thereof B Ault, M Sostek, E Orlemans, JR Plachetka US Patent 9,220,698, 2015 | 121 | 2015 |
| Method for treating a patient at risk for developing an NSAID-associated ulcer B Ault, C Hwang, E Orlemans, JR Plachetka, M Sostek US Patent 8,945,621, 2015 | 116 | 2015 |
| Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis MB Fennerty, JF Johanson, C Hwang, M Sostek Alimentary pharmacology & therapeutics 21 (4), 455-463, 2005 | 116 | 2005 |
| Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone JL Goldstein, MC Hochberg, JG Fort, Y Zhang, C Hwang, M Sostek Alimentary pharmacology & therapeutics 32 (3), 401-413, 2010 | 101 | 2010 |
| Method for delivering a pharmaceutical composition to patient in need thereof B Ault, E Orlemans, JR Plachetka, M Sostek US Patent 9,393,208, 2016 | 100 | 2016 |
| Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis PO Katz, GG Ginsberg, PE Hoyle, MB Sostek, JT Monyak, DG Silberg Alimentary pharmacology & therapeutics 25 (5), 617-628, 2007 | 95 | 2007 |
| Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover study PO Katz, DO Castell, Y Chen, T Andersson, MB Sostek Alimentary pharmacology & therapeutics 20 (4), 399-406, 2004 | 85 | 2004 |
| Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion DC Metz, MB Sostek, P Ruszniewski, CE Forsmark, J Monyak, ... Official journal of the American College of Gastroenterology| ACG 102 (12 …, 2007 | 84 | 2007 |
| Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials MC Hochberg, JG Fort, O Svensson, C Hwang, M Sostek Current medical research and opinion 27 (6), 1243-1253, 2011 | 69 | 2011 |
| Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response J Tack, J Lappalainen, U Diva, R Tummala, M Sostek United European Gastroenterology Journal 3 (5), 471-480, 2015 | 68 | 2015 |
| Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams KR DeVault, JF Johanson, DA Johnson, S Liu, MB Sostek Clinical Gastroenterology and Hepatology 4 (7), 852-859, 2006 | 67 | 2006 |
| Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole MB Sostek, Y Chen, T Andersson British journal of clinical pharmacology 64 (3), 386-390, 2007 | 66 | 2007 |
| Treatment patterns, healthcare utilization, and costs of chronic opioid treatment for non-cancer pain in the United States DM Kern, S Zhou, S Chavoshi, O Tunceli, M Sostek, J Singer, ... Am J Manag Care 21 (3), e222-e234, 2015 | 57 | 2015 |
